 "Suven Life gets patents for neuro-degenerative drug from Israel, Mexico")
Drug firm Suven Life Sciences has been granted a patent each by Israel and Mexico for a drug used for the treatment of neuro-degenerative diseases.
In a BSE filing today, Suven Life said it has been granted "one product patent from Israel and one product patent from Mexico corresponding to the New Chemical Entities for the treatment of disorders associated with neuro-degenerative diseases".
The patents are valid till 2032, the company added.
Suven said that the granted claims of the patents... are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder, Huntington's disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 10 granted patents from Israel and 21 from Mexico.
"These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II," Suven said.
Suven Life Sciences shares were trading 1.66% up at Rs 218 apiece on BSE in the morning trade.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%